Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity

Chrysothemis C. Brown(Memorial Sloan Kettering Cancer Center), Herman Gudjonson(Great Ormond Street Hospital), Yuri Pritykin(Memorial Sloan Kettering Cancer Center), Deeksha Deep(Memorial Sloan Kettering Cancer Center), Vincent‐Philippe Lavallée(Memorial Sloan Kettering Cancer Center), Alejandra Mendoza(Memorial Sloan Kettering Cancer Center), Rachel M. Fromme(Memorial Sloan Kettering Cancer Center), Linas Mažutis(Memorial Sloan Kettering Cancer Center), Charlotte E. Ariyan(Memorial Sloan Kettering Cancer Center), Christina S. Leslie(Memorial Sloan Kettering Cancer Center), Dana Pe’er(Memorial Sloan Kettering Cancer Center), Alexander Y. Rudensky(Memorial Sloan Kettering Cancer Center)
Cell
October 1, 2019
Cited by 613Open Access
Full Text

Abstract

Dendritic cells (DCs) play a critical role in orchestrating adaptive immune responses due to their unique ability to initiate T cell responses and direct their differentiation into effector lineages. Classical DCs have been divided into two subsets, cDC1 and cDC2, based on phenotypic markers and their distinct abilities to prime CD8 and CD4 T cells. While the transcriptional regulation of the cDC1 subset has been well characterized, cDC2 development and function remain poorly understood. By combining transcriptional and chromatin analyses with genetic reporter expression, we identified two principal cDC2 lineages defined by distinct developmental pathways and transcriptional regulators, including T-bet and RORγt, two key transcription factors known to define innate and adaptive lymphocyte subsets. These novel cDC2 lineages were characterized by distinct metabolic and functional programs. Extending our findings to humans revealed conserved DC heterogeneity and the presence of the newly defined cDC2 subsets in human cancer.


Related Papers

No related papers found

Powered by citation graph analysis